Biology of Bladder Cancer (R01 Clinical Trial Optional) | PAR 25 129

Opportunity Information: Apply for PAR 25 129

The National Institutes of Health (NIH) is offering an R01 grant opportunity titled "Biology of Bladder Cancer (R01 Clinical Trial Optional)" (Funding Opportunity Number: PAR-25-129). This Notice of Funding Opportunity is focused on supporting research that explains the fundamental biology of bladder cancer and the underlying mechanisms that drive how it starts, progresses, and becomes malignant. The main idea is to move beyond lists of mutations and molecular profiles and instead build a clearer, mechanism-based understanding of what those changes do in cells and tissues over time, and how they translate into tumor behavior, recurrence, and clinical outcomes. Clinical trials are optional under this announcement, meaning applicants may propose studies that include clinical trial components, but they are not required.

A central motivation for the program is that bladder cancer remains a major public health problem in the United States and worldwide, with an especially heavy medical burden due to its high incidence and frequent recurrence. Even though the field has made meaningful strides in identifying mutated genes and characterizing tumor subtypes through molecular profiling, NIH emphasizes that key biological questions remain unanswered. The NOFO highlights a gap between descriptive datasets and true biological understanding: relatively little is known about the molecular and cellular mechanisms that actually cause bladder tumors to form, evolve, invade, resist treatment, or recur. The opportunity is therefore aimed at studies that can explain cause-and-effect relationships, such as how specific molecular events reshape signaling pathways, cell states, tissue organization, microenvironment interactions, or immune responses in ways that enable cancer development and progression.

Another major priority is strengthening the knowledge base for the normal bladder itself. The NOFO explicitly notes that basic understanding of normal bladder biology at the molecular, cellular, and organ levels is limited, and that this limitation slows progress in cancer research. By encouraging projects that investigate both normal and cancer processes, NIH is signaling that strong proposals may compare normal urothelial biology to malignant transformation, define baseline cell types and functions, characterize normal regeneration and injury responses, or map how normal bladder tissues respond to stressors that may contribute to carcinogenesis. The broader purpose is to establish fundamental reference points so researchers can more precisely identify what changes in cancer, when it changes, and why those changes matter.

The solicitation encourages multidisciplinary research teams and approaches, reflecting the complexity of bladder cancer biology. Competitive applications may integrate expertise across cancer biology, urology, pathology, genomics, epigenetics, immunology, computational biology, systems biology, bioengineering, and other fields. The NOFO also encourages the use of clinical specimens, which can include patient-derived tissues and biospecimens that anchor mechanistic work to real disease biology and improve translational relevance. Projects that connect observations from human samples to functional experiments, or that bridge normal bladder biology with tumor biology, align closely with the program's stated interests.

This is a discretionary grant mechanism using the NIH R01 funding instrument, which typically supports substantial, multi-year investigator-initiated research projects. The opportunity falls under health and education activity categories and lists CFDA numbers 93.393 and 93.396. The original closing date is 2025-09-07, and the opportunity was created on 2024-11-19. An award ceiling and the expected number of awards are not specified in the provided source information, which usually means applicants should consult the full announcement for budget parameters and funding expectations.

Eligibility is broad and includes many organization types commonly able to apply for NIH funding. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as listed); for-profit organizations other than small businesses; and small businesses. The NOFO also explicitly calls out additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-domestic (non-U.S.) entities (foreign organizations). This wide eligibility reflects an intent to draw strong bladder cancer biology proposals from diverse institutional settings and to support broad participation, including from institutions serving historically underrepresented communities and from international research organizations.

Overall, this NOFO is aimed at advancing bladder cancer research from descriptive characterization to deeper mechanistic insight, while also building a stronger foundation in normal bladder biology. The expected payoff is more precise understanding of the biological processes that drive initiation, progression, and recurrence, which in turn can inform better prevention strategies, improved biomarkers, and more effective interventions for patients.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Biology of Bladder Cancer (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.396.
• This funding opportunity was created on 2024-11-19.
• Applicants must submit their applications by 2025-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 25 129

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: